You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
斯微生物夥百度研究院以人工智能加速mRNA疫苗及藥物研發
內地生物科技公司斯微生物宣布,與百度(09888.HK)(BIDU.US)旗下百度研究院達成合作,以人工智能(AI)及生物計算技術賦能生命科學領域的研究,加強現有的新冠mRNA疫苗AI序列優化算法合作基礎。 除擴大線性mRNA算法優化研究外,雙方並將嘗試開展環狀RNA等序列設計迭代技術的開發,通過提升mRNA的穩定性和翻譯效率來提高抗原蛋白的表達量及持續時間,有望將mRNA的優勢更加充分的體現,即提升效率及安全性,降低生產成本。 斯微生物創始人兼CEO李航文表示,以AI技術應用於生物製藥領域有利於打造交叉學科的藥物研發平台,有利於源頭創新,預期與百度AI算法的聯合也將為公司在研管線和RNA平台帶來更大的提升,有望推出更多同類領先(best-in-class)產品。 年初有市場消息指,斯微生物計劃最快今年下半年來港上市,集資4億美元,中金及富瑞正協助準備上市工作。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account